Literature DB >> 29800127

Implications of Nine Risk Prediction Models for Selecting Ever-Smokers for Computed Tomography Lung Cancer Screening.

Hormuzd A Katki1, Stephanie A Kovalchik1, Lucia C Petito1, Li C Cheung1, Eric Jacobs2, Ahmedin Jemal2, Christine D Berg1, Anil K Chaturvedi1.   

Abstract

Background: Lung cancer screening guidelines recommend using individualized risk models to refer ever-smokers for screening. However, different models select different screening populations. The performance of each model in selecting ever-smokers for screening is unknown. Objective: To compare the U.S. screening populations selected by 9 lung cancer risk models (the Bach model; the Spitz model; the Liverpool Lung Project [LLP] model; the LLP Incidence Risk Model [LLPi]; the Hoggart model; the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Model 2012 [PLCOM2012]; the Pittsburgh Predictor; the Lung Cancer Risk Assessment Tool [LCRAT]; and the Lung Cancer Death Risk Assessment Tool [LCDRAT]) and to examine their predictive performance in 2 cohorts. Design: Population-based prospective studies. Setting: United States. Participants: Models selected U.S. screening populations by using data from the National Health Interview Survey from 2010 to 2012. Model performance was evaluated using data from 337 388 ever-smokers in the National Institutes of Health-AARP Diet and Health Study and 72 338 ever-smokers in the CPS-II (Cancer Prevention Study II) Nutrition Survey cohort. Measurements: Model calibration (ratio of model-predicted to observed cases [expected-observed ratio]) and discrimination (area under the curve [AUC]).
Results: At a 5-year risk threshold of 2.0%, the models chose U.S. screening populations ranging from 7.6 million to 26 million ever-smokers. These disagreements occurred because, in both validation cohorts, 4 models (the Bach model, PLCOM2012, LCRAT, and LCDRAT) were well-calibrated (expected-observed ratio range, 0.92 to 1.12) and had higher AUCs (range, 0.75 to 0.79) than 5 models that generally overestimated risk (expected-observed ratio range, 0.83 to 3.69) and had lower AUCs (range, 0.62 to 0.75). The 4 best-performing models also had the highest sensitivity at a fixed specificity (and vice versa) and similar discrimination at a fixed risk threshold. These models showed better agreement on size of the screening population (7.6 million to 10.9 million) and achieved consensus on 73% of persons chosen. Limitation: No consensus on risk thresholds for screening.
Conclusion: The 9 lung cancer risk models chose widely differing U.S. screening populations. However, 4 models (the Bach model, PLCOM2012, LCRAT, and LCDRAT) most accurately predicted risk and performed best in selecting ever-smokers for screening. Primary Funding Source: Intramural Research Program of the National Institutes of Health/National Cancer Institute.

Entities:  

Mesh:

Year:  2018        PMID: 29800127      PMCID: PMC6557386          DOI: 10.7326/M17-2701

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  31 in total

1.  Lung Cancer Screening With Low-Dose Computed Tomography in the United States-2010 to 2015.

Authors:  Ahmedin Jemal; Stacey A Fedewa
Journal:  JAMA Oncol       Date:  2017-09-01       Impact factor: 31.777

2.  Who Should Be Screened for Lung Cancer? And Who Gets to Decide?

Authors:  Michael K Gould
Journal:  JAMA       Date:  2016-06-07       Impact factor: 56.272

Review 3.  Benefits and harms of CT screening for lung cancer: a systematic review.

Authors:  Peter B Bach; Joshua N Mirkin; Thomas K Oliver; Christopher G Azzoli; Donald A Berry; Otis W Brawley; Tim Byers; Graham A Colditz; Michael K Gould; James R Jett; Anita L Sabichi; Rebecca Smith-Bindman; Douglas E Wood; Amir Qaseem; Frank C Detterbeck
Journal:  JAMA       Date:  2012-06-13       Impact factor: 56.272

4.  A simple model for predicting lung cancer occurrence in a lung cancer screening program: The Pittsburgh Predictor.

Authors:  David O Wilson; Joel Weissfeld
Journal:  Lung Cancer       Date:  2015-03-28       Impact factor: 5.705

Review 5.  Application of risk prediction models to lung cancer screening: a review.

Authors:  Martin C Tammemägi
Journal:  J Thorac Imaging       Date:  2015-03       Impact factor: 3.000

6.  The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics.

Authors:  Eugenia E Calle; Carmen Rodriguez; Eric J Jacobs; M Lyn Almon; Ann Chao; Marjorie L McCullough; Heather S Feigelson; Michael J Thun
Journal:  Cancer       Date:  2002-05-01       Impact factor: 6.860

7.  Validation of a model of lung cancer risk prediction among smokers.

Authors:  Kathleen A Cronin; Mitchell H Gail; Zhaohui Zou; Peter B Bach; Jarmo Virtamo; Demetrius Albanes
Journal:  J Natl Cancer Inst       Date:  2006-05-03       Impact factor: 13.506

8.  Targeting of low-dose CT screening according to the risk of lung-cancer death.

Authors:  Anil K Chaturvedi; Hormuzd A Katki; Stephanie A Kovalchik; Martin Tammemagi; Christine D Berg; Neil E Caporaso; Tom L Riley; Mary Korch; Gerard A Silvestri
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245

9.  Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts.

Authors:  Martin C Tammemägi; Timothy R Church; William G Hocking; Gerard A Silvestri; Paul A Kvale; Thomas L Riley; John Commins; Christine D Berg
Journal:  PLoS Med       Date:  2014-12-02       Impact factor: 11.069

10.  The LLP risk model: an individual risk prediction model for lung cancer.

Authors:  A Cassidy; J P Myles; M van Tongeren; R D Page; T Liloglou; S W Duffy; J K Field
Journal:  Br J Cancer       Date:  2007-12-18       Impact factor: 7.640

View more
  45 in total

1.  Atypical pulmonary alveolar proteinosis presenting as a mixed nodular ground-glass opacity with focal mucinosis mimicking lung cancer.

Authors:  Tsutomu Shinohara; Hiroyuki Hino; Shino Imanishi; Keishi Naruse; Yuji Ohtsuki; Fumitaka Ogushi
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

2.  Lung Cancer Screening Benefits and Harms Stratified by Patient Risk: Information to Improve Patient Decision Aids.

Authors:  Christina Bellinger; Paul Pinsky; Kristie Foley; Douglas Case; Ajay Dharod; David Miller
Journal:  Ann Am Thorac Soc       Date:  2019-04

3.  Contemporary Implications of U.S. Preventive Services Task Force and Risk-Based Guidelines for Lung Cancer Screening Eligibility in the United States.

Authors:  Rebecca Landy; Li C Cheung; Christine D Berg; Anil K Chaturvedi; Hilary A Robbins; Hormuzd A Katki
Journal:  Ann Intern Med       Date:  2019-06-04       Impact factor: 25.391

4.  Lung cancer screening: how do we make it better?

Authors:  David O Wilson; Juan Pablo de Torres
Journal:  Quant Imaging Med Surg       Date:  2020-02

Review 5.  Disparities in Lung Cancer Screening: A Review.

Authors:  Diane N Haddad; Kim L Sandler; Louise M Henderson; M Patricia Rivera; Melinda C Aldrich
Journal:  Ann Am Thorac Soc       Date:  2020-04

6.  Lung cancer screening: tell me more about post-test risk.

Authors:  Mario Silva; Gianluca Milanese; Ugo Pastorino; Nicola Sverzellati
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

7.  Life-Gained-Based Versus Risk-Based Selection of Smokers for Lung Cancer Screening.

Authors:  Li C Cheung; Christine D Berg; Philip E Castle; Hormuzd A Katki; Anil K Chaturvedi
Journal:  Ann Intern Med       Date:  2019-10-22       Impact factor: 25.391

Review 8.  Selecting lung cancer screenees using risk prediction models-where do we go from here.

Authors:  Martin C Tammemägi
Journal:  Transl Lung Cancer Res       Date:  2018-06

9.  Targeted Incentive Programs For Lung Cancer Screening Can Improve Population Health And Economic Efficiency.

Authors:  David D Kim; Joshua T Cohen; John B Wong; Babak Mohit; A Mark Fendrick; David M Kent; Peter J Neumann
Journal:  Health Aff (Millwood)       Date:  2019-01       Impact factor: 6.301

10.  Effects of Personalized Risk Information on Patients Referred for Lung Cancer Screening with Low-Dose CT.

Authors:  Paul K J Han; Christine Lary; Adam Black; Caitlin Gutheil; Hayley Mandeville; Jason Yahwak; Mayuko Fukunaga
Journal:  Med Decis Making       Date:  2019-10-20       Impact factor: 2.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.